Michael Bromberg, MD, PhD, Chief of the Section of Hematology at Temple University Hospital, discussed with HealthCentral two newly approved gene therapies for patients with the genetic blood disorder transfusion-dependent beta thalassemia.
IMPORTANT: Beginning at 8:00 AM on July 22, Temple University Hospital – Main Campus (Broad and Ontario Streets) will no longer provide Labor and Delivery services. All childbirth services will be relocated to our new hospital location.
Michael Bromberg, MD, PhD, Chief of the Section of Hematology at Temple University Hospital, discussed with HealthCentral two newly approved gene therapies for patients with the genetic blood disorder transfusion-dependent beta thalassemia.
Researchers have developed a new treatment program for type 2 diabetes, called GEM, which offers an individualized approach that teases out the few foods that spike blood sugar the most so patients can focus on reducing those foods without dieting.
Read MoreThe Hepatitis C Allies of Philadelphia hosted an evening celebrating Hepatitis Awareness Month.
Read More